nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0575	0.137	CbGbCtD
L-DOPA—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0541	0.129	CbGbCtD
L-DOPA—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0541	0.129	CbGbCtD
L-DOPA—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0489	0.116	CbGbCtD
L-DOPA—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0489	0.116	CbGbCtD
L-DOPA—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0422	0.1	CbGbCtD
L-DOPA—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.041	0.0974	CbGbCtD
L-DOPA—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0371	0.0881	CbGbCtD
L-DOPA—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0371	0.0881	CbGbCtD
L-DOPA—DDC—nerve—acquired immunodeficiency syndrome	0.00622	0.053	CbGeAlD
L-DOPA—L-Tyrosine—TAT—acquired immunodeficiency syndrome	0.00499	0.579	CrCbGaD
L-DOPA—DDC—blood plasma—acquired immunodeficiency syndrome	0.00471	0.0401	CbGeAlD
L-DOPA—DRD1—nerve—acquired immunodeficiency syndrome	0.00457	0.0389	CbGeAlD
L-DOPA—PSIP1—retina—acquired immunodeficiency syndrome	0.00452	0.0385	CbGeAlD
L-DOPA—PSIP1—lymphoid tissue—acquired immunodeficiency syndrome	0.00321	0.0274	CbGeAlD
L-DOPA—PSIP1—digestive system—acquired immunodeficiency syndrome	0.00317	0.027	CbGeAlD
L-DOPA—PSIP1—blood—acquired immunodeficiency syndrome	0.00302	0.0257	CbGeAlD
L-DOPA—PSIP1—bone marrow—acquired immunodeficiency syndrome	0.00292	0.0249	CbGeAlD
L-DOPA—PSIP1—spinal cord—acquired immunodeficiency syndrome	0.00291	0.0248	CbGeAlD
L-DOPA—L-Phenylalanine—TAT—acquired immunodeficiency syndrome	0.0029	0.336	CrCbGaD
L-DOPA—PSIP1—vagina—acquired immunodeficiency syndrome	0.0028	0.0239	CbGeAlD
L-DOPA—DRD2—nerve—acquired immunodeficiency syndrome	0.0027	0.023	CbGeAlD
L-DOPA—PSIP1—lung—acquired immunodeficiency syndrome	0.00265	0.0226	CbGeAlD
L-DOPA—SLC7A8—skin of body—acquired immunodeficiency syndrome	0.00261	0.0223	CbGeAlD
L-DOPA—PSIP1—nervous system—acquired immunodeficiency syndrome	0.00245	0.0209	CbGeAlD
L-DOPA—PSIP1—central nervous system—acquired immunodeficiency syndrome	0.00236	0.0201	CbGeAlD
L-DOPA—SLC7A5—retina—acquired immunodeficiency syndrome	0.00231	0.0197	CbGeAlD
L-DOPA—SLC7A5—skin of body—acquired immunodeficiency syndrome	0.00203	0.0173	CbGeAlD
L-DOPA—PSIP1—brain—acquired immunodeficiency syndrome	0.00188	0.016	CbGeAlD
L-DOPA—SLC7A8—vagina—acquired immunodeficiency syndrome	0.00185	0.0157	CbGeAlD
L-DOPA—PSIP1—lymph node—acquired immunodeficiency syndrome	0.00181	0.0154	CbGeAlD
L-DOPA—DRD5—lymphoid tissue—acquired immunodeficiency syndrome	0.00176	0.015	CbGeAlD
L-DOPA—SLC7A8—lung—acquired immunodeficiency syndrome	0.00175	0.0149	CbGeAlD
L-DOPA—SLC7A5—lymphoid tissue—acquired immunodeficiency syndrome	0.00164	0.014	CbGeAlD
L-DOPA—SLC7A5—digestive system—acquired immunodeficiency syndrome	0.00162	0.0138	CbGeAlD
L-DOPA—SLC7A8—nervous system—acquired immunodeficiency syndrome	0.00162	0.0138	CbGeAlD
L-DOPA—DRD4—brain—acquired immunodeficiency syndrome	0.00156	0.0133	CbGeAlD
L-DOPA—SLC7A8—central nervous system—acquired immunodeficiency syndrome	0.00156	0.0133	CbGeAlD
L-DOPA—SLC7A5—blood—acquired immunodeficiency syndrome	0.00154	0.0131	CbGeAlD
L-DOPA—DDC—lung—acquired immunodeficiency syndrome	0.00151	0.0129	CbGeAlD
L-DOPA—SLC7A5—bone marrow—acquired immunodeficiency syndrome	0.00149	0.0127	CbGeAlD
L-DOPA—SLC7A5—spinal cord—acquired immunodeficiency syndrome	0.00149	0.0127	CbGeAlD
L-DOPA—DRD3—nervous system—acquired immunodeficiency syndrome	0.00144	0.0122	CbGeAlD
L-DOPA—SLC7A5—vagina—acquired immunodeficiency syndrome	0.00143	0.0122	CbGeAlD
L-DOPA—DDC—nervous system—acquired immunodeficiency syndrome	0.0014	0.0119	CbGeAlD
L-DOPA—DRD3—central nervous system—acquired immunodeficiency syndrome	0.00138	0.0118	CbGeAlD
L-DOPA—SLC7A5—lung—acquired immunodeficiency syndrome	0.00135	0.0115	CbGeAlD
L-DOPA—DDC—central nervous system—acquired immunodeficiency syndrome	0.00135	0.0115	CbGeAlD
L-DOPA—DRD5—nervous system—acquired immunodeficiency syndrome	0.00135	0.0115	CbGeAlD
L-DOPA—SLC15A1—digestive system—acquired immunodeficiency syndrome	0.00135	0.0115	CbGeAlD
L-DOPA—DRD5—central nervous system—acquired immunodeficiency syndrome	0.0013	0.011	CbGeAlD
L-DOPA—SLC16A10—lymphoid tissue—acquired immunodeficiency syndrome	0.00126	0.0107	CbGeAlD
L-DOPA—SLC7A5—nervous system—acquired immunodeficiency syndrome	0.00125	0.0107	CbGeAlD
L-DOPA—SLC7A8—brain—acquired immunodeficiency syndrome	0.00124	0.0105	CbGeAlD
L-DOPA—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00123	0.0105	CbGeAlD
L-DOPA—SLC7A5—central nervous system—acquired immunodeficiency syndrome	0.00121	0.0103	CbGeAlD
L-DOPA—SLC7A8—lymph node—acquired immunodeficiency syndrome	0.00119	0.0102	CbGeAlD
L-DOPA—SLC15A1—vagina—acquired immunodeficiency syndrome	0.00119	0.0101	CbGeAlD
L-DOPA—SLC16A10—blood—acquired immunodeficiency syndrome	0.00118	0.0101	CbGeAlD
L-DOPA—DRD2—retina—acquired immunodeficiency syndrome	0.00112	0.00952	CbGeAlD
L-DOPA—DRD3—brain—acquired immunodeficiency syndrome	0.0011	0.00935	CbGeAlD
L-DOPA—SLC16A10—vagina—acquired immunodeficiency syndrome	0.0011	0.00933	CbGeAlD
L-DOPA—DDC—brain—acquired immunodeficiency syndrome	0.00107	0.00911	CbGeAlD
L-DOPA—SLC16A10—lung—acquired immunodeficiency syndrome	0.00104	0.00882	CbGeAlD
L-DOPA—DDC—lymph node—acquired immunodeficiency syndrome	0.00103	0.0088	CbGeAlD
L-DOPA—DRD5—brain—acquired immunodeficiency syndrome	0.00103	0.00876	CbGeAlD
L-DOPA—DRD1—nervous system—acquired immunodeficiency syndrome	0.00103	0.00875	CbGeAlD
L-DOPA—DRD1—central nervous system—acquired immunodeficiency syndrome	0.00099	0.00843	CbGeAlD
L-DOPA—SLC7A5—brain—acquired immunodeficiency syndrome	0.000958	0.00816	CbGeAlD
L-DOPA—SLC7A5—lymph node—acquired immunodeficiency syndrome	0.000926	0.00788	CbGeAlD
L-DOPA—DRD1—brain—acquired immunodeficiency syndrome	0.000786	0.00669	CbGeAlD
L-DOPA—SLC16A10—lymph node—acquired immunodeficiency syndrome	0.000709	0.00604	CbGeAlD
L-DOPA—DRD2—lung—acquired immunodeficiency syndrome	0.000656	0.00559	CbGeAlD
L-DOPA—DRD2—nervous system—acquired immunodeficiency syndrome	0.000607	0.00517	CbGeAlD
L-DOPA—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000585	0.00498	CbGeAlD
L-DOPA—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000472	0.00402	CbGeAlD
L-DOPA—DRD2—brain—acquired immunodeficiency syndrome	0.000464	0.00395	CbGeAlD
L-DOPA—CYP2D6—blood—acquired immunodeficiency syndrome	0.00045	0.00383	CbGeAlD
L-DOPA—Epinephrine—TNF—acquired immunodeficiency syndrome	0.000448	0.0519	CrCbGaD
L-DOPA—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000365	0.00311	CbGeAlD
L-DOPA—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000351	0.00299	CbGeAlD
L-DOPA—Liothyronine—ALB—acquired immunodeficiency syndrome	0.000283	0.0329	CrCbGaD
L-DOPA—CYP2D6—brain—acquired immunodeficiency syndrome	0.000279	0.00238	CbGeAlD
L-DOPA—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000277	0.000865	CcSEcCtD
L-DOPA—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000277	0.000865	CcSEcCtD
L-DOPA—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000275	0.000861	CcSEcCtD
L-DOPA—Headache—Didanosine—acquired immunodeficiency syndrome	0.000275	0.00086	CcSEcCtD
L-DOPA—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000275	0.000859	CcSEcCtD
L-DOPA—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000274	0.000858	CcSEcCtD
L-DOPA—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000274	0.000857	CcSEcCtD
L-DOPA—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000274	0.000857	CcSEcCtD
L-DOPA—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000274	0.000857	CcSEcCtD
L-DOPA—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000273	0.000855	CcSEcCtD
L-DOPA—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.000855	CcSEcCtD
L-DOPA—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000273	0.000854	CcSEcCtD
L-DOPA—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000273	0.000853	CcSEcCtD
L-DOPA—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000272	0.000852	CcSEcCtD
L-DOPA—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.000852	CcSEcCtD
L-DOPA—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.00085	CcSEcCtD
L-DOPA—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000271	0.000849	CcSEcCtD
L-DOPA—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000271	0.000848	CcSEcCtD
L-DOPA—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000271	0.000847	CcSEcCtD
L-DOPA—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00027	0.000846	CcSEcCtD
L-DOPA—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00027	0.000845	CcSEcCtD
L-DOPA—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00027	0.000843	CcSEcCtD
L-DOPA—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000269	0.000842	CcSEcCtD
L-DOPA—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000269	0.000842	CcSEcCtD
L-DOPA—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000269	0.000841	CcSEcCtD
L-DOPA—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000269	0.00084	CcSEcCtD
L-DOPA—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000268	0.000838	CcSEcCtD
L-DOPA—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.000838	CcSEcCtD
L-DOPA—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000268	0.000837	CcSEcCtD
L-DOPA—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000267	0.000835	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000266	0.000832	CcSEcCtD
L-DOPA—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000266	0.000831	CcSEcCtD
L-DOPA—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000266	0.000831	CcSEcCtD
L-DOPA—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000265	0.00083	CcSEcCtD
L-DOPA—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000265	0.00083	CcSEcCtD
L-DOPA—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000265	0.000829	CcSEcCtD
L-DOPA—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000265	0.000828	CcSEcCtD
L-DOPA—Pain—Indinavir—acquired immunodeficiency syndrome	0.000263	0.000824	CcSEcCtD
L-DOPA—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000263	0.000824	CcSEcCtD
L-DOPA—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000263	0.000823	CcSEcCtD
L-DOPA—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000263	0.000823	CcSEcCtD
L-DOPA—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.000823	CcSEcCtD
L-DOPA—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000263	0.000822	CcSEcCtD
L-DOPA—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.00082	CcSEcCtD
L-DOPA—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000262	0.000819	CcSEcCtD
L-DOPA—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000262	0.000818	CcSEcCtD
L-DOPA—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000261	0.000817	CcSEcCtD
L-DOPA—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000261	0.000817	CcSEcCtD
L-DOPA—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000261	0.000816	CcSEcCtD
L-DOPA—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000261	0.000815	CcSEcCtD
L-DOPA—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00026	0.000814	CcSEcCtD
L-DOPA—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.000813	CcSEcCtD
L-DOPA—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00026	0.000812	CcSEcCtD
L-DOPA—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00026	0.000812	CcSEcCtD
L-DOPA—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000259	0.000811	CcSEcCtD
L-DOPA—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000259	0.000809	CcSEcCtD
L-DOPA—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000259	0.000809	CcSEcCtD
L-DOPA—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000258	0.000806	CcSEcCtD
L-DOPA—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000258	0.000805	CcSEcCtD
L-DOPA—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000257	0.000803	CcSEcCtD
L-DOPA—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000256	0.000801	CcSEcCtD
L-DOPA—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000255	0.000799	CcSEcCtD
L-DOPA—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000255	0.000796	CcSEcCtD
L-DOPA—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000254	0.000794	CcSEcCtD
L-DOPA—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000253	0.000792	CcSEcCtD
L-DOPA—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000253	0.000791	CcSEcCtD
L-DOPA—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000253	0.000791	CcSEcCtD
L-DOPA—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000253	0.000791	CcSEcCtD
L-DOPA—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000253	0.000791	CcSEcCtD
L-DOPA—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000252	0.000789	CcSEcCtD
L-DOPA—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000252	0.000788	CcSEcCtD
L-DOPA—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000252	0.000788	CcSEcCtD
L-DOPA—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000252	0.000788	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000251	0.000786	CcSEcCtD
L-DOPA—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.000785	CcSEcCtD
L-DOPA—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000251	0.000785	CcSEcCtD
L-DOPA—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000251	0.000785	CcSEcCtD
L-DOPA—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00025	0.000782	CcSEcCtD
L-DOPA—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.00025	0.000782	CcSEcCtD
L-DOPA—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000249	0.000779	CcSEcCtD
L-DOPA—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000249	0.000778	CcSEcCtD
L-DOPA—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000249	0.000778	CcSEcCtD
L-DOPA—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000249	0.000778	CcSEcCtD
L-DOPA—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000249	0.000778	CcSEcCtD
L-DOPA—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000248	0.000777	CcSEcCtD
L-DOPA—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000248	0.000776	CcSEcCtD
L-DOPA—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000248	0.000775	CcSEcCtD
L-DOPA—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000248	0.000774	CcSEcCtD
L-DOPA—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000247	0.000773	CcSEcCtD
L-DOPA—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000247	0.000771	CcSEcCtD
L-DOPA—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000246	0.000769	CcSEcCtD
L-DOPA—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000246	0.000768	CcSEcCtD
L-DOPA—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000245	0.000767	CcSEcCtD
L-DOPA—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000245	0.000765	CcSEcCtD
L-DOPA—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000244	0.000763	CcSEcCtD
L-DOPA—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000244	0.000762	CcSEcCtD
L-DOPA—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000244	0.000762	CcSEcCtD
L-DOPA—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000243	0.00076	CcSEcCtD
L-DOPA—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000243	0.000759	CcSEcCtD
L-DOPA—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000242	0.000758	CcSEcCtD
L-DOPA—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000242	0.000757	CcSEcCtD
L-DOPA—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000241	0.000754	CcSEcCtD
L-DOPA—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000241	0.000754	CcSEcCtD
L-DOPA—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000241	0.000753	CcSEcCtD
L-DOPA—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000241	0.000753	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.00024	0.000752	CcSEcCtD
L-DOPA—Rash—Stavudine—acquired immunodeficiency syndrome	0.00024	0.000752	CcSEcCtD
L-DOPA—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.00024	0.000751	CcSEcCtD
L-DOPA—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00024	0.000751	CcSEcCtD
L-DOPA—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00024	0.00075	CcSEcCtD
L-DOPA—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.00024	0.000749	CcSEcCtD
L-DOPA—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00024	0.000749	CcSEcCtD
L-DOPA—Headache—Stavudine—acquired immunodeficiency syndrome	0.000239	0.000747	CcSEcCtD
L-DOPA—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000239	0.000747	CcSEcCtD
L-DOPA—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000238	0.000746	CcSEcCtD
L-DOPA—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000238	0.000745	CcSEcCtD
L-DOPA—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000238	0.000745	CcSEcCtD
L-DOPA—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000238	0.000744	CcSEcCtD
L-DOPA—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000238	0.000743	CcSEcCtD
L-DOPA—Rash—Abacavir—acquired immunodeficiency syndrome	0.000237	0.00074	CcSEcCtD
L-DOPA—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000237	0.00074	CcSEcCtD
L-DOPA—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000236	0.00074	CcSEcCtD
L-DOPA—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000236	0.000739	CcSEcCtD
L-DOPA—Headache—Abacavir—acquired immunodeficiency syndrome	0.000235	0.000736	CcSEcCtD
L-DOPA—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000234	0.000733	CcSEcCtD
L-DOPA—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000234	0.000733	CcSEcCtD
L-DOPA—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000233	0.000728	CcSEcCtD
L-DOPA—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000728	CcSEcCtD
L-DOPA—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000232	0.000724	CcSEcCtD
L-DOPA—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000232	0.000724	CcSEcCtD
L-DOPA—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000231	0.000723	CcSEcCtD
L-DOPA—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000231	0.000723	CcSEcCtD
L-DOPA—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00023	0.00072	CcSEcCtD
L-DOPA—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00023	0.000718	CcSEcCtD
L-DOPA—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00023	0.000718	CcSEcCtD
L-DOPA—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000229	0.000716	CcSEcCtD
L-DOPA—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000229	0.000715	CcSEcCtD
L-DOPA—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000228	0.000712	CcSEcCtD
L-DOPA—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000227	0.00071	CcSEcCtD
L-DOPA—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000227	0.00071	CcSEcCtD
L-DOPA—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000227	0.000709	CcSEcCtD
L-DOPA—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000227	0.000709	CcSEcCtD
L-DOPA—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000226	0.000708	CcSEcCtD
L-DOPA—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.000705	CcSEcCtD
L-DOPA—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000224	0.000701	CcSEcCtD
L-DOPA—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000224	0.0007	CcSEcCtD
L-DOPA—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000223	0.000697	CcSEcCtD
L-DOPA—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000223	0.000696	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000222	0.000695	CcSEcCtD
L-DOPA—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000222	0.000694	CcSEcCtD
L-DOPA—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000221	0.000692	CcSEcCtD
L-DOPA—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000221	0.000691	CcSEcCtD
L-DOPA—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000221	0.000691	CcSEcCtD
L-DOPA—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000221	0.000691	CcSEcCtD
L-DOPA—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00022	0.000689	CcSEcCtD
L-DOPA—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00022	0.000689	CcSEcCtD
L-DOPA—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00022	0.000689	CcSEcCtD
L-DOPA—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00022	0.000689	CcSEcCtD
L-DOPA—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000219	0.000685	CcSEcCtD
L-DOPA—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000218	0.000682	CcSEcCtD
L-DOPA—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000218	0.000682	CcSEcCtD
L-DOPA—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.000674	CcSEcCtD
L-DOPA—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000214	0.000671	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000214	0.000669	CcSEcCtD
L-DOPA—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000214	0.000669	CcSEcCtD
L-DOPA—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000214	0.000668	CcSEcCtD
L-DOPA—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000212	0.000664	CcSEcCtD
L-DOPA—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000212	0.000664	CcSEcCtD
L-DOPA—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000212	0.000663	CcSEcCtD
L-DOPA—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000212	0.000663	CcSEcCtD
L-DOPA—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000211	0.000659	CcSEcCtD
L-DOPA—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000211	0.000659	CcSEcCtD
L-DOPA—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000211	0.000659	CcSEcCtD
L-DOPA—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000211	0.000659	CcSEcCtD
L-DOPA—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.000657	CcSEcCtD
L-DOPA—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000209	0.000653	CcSEcCtD
L-DOPA—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000209	0.000653	CcSEcCtD
L-DOPA—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000209	0.000653	CcSEcCtD
L-DOPA—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000208	0.000651	CcSEcCtD
L-DOPA—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000208	0.000649	CcSEcCtD
L-DOPA—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000206	0.000644	CcSEcCtD
L-DOPA—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000206	0.000643	CcSEcCtD
L-DOPA—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000205	0.000642	CcSEcCtD
L-DOPA—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000205	0.00064	CcSEcCtD
L-DOPA—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000204	0.000639	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000204	0.000638	CcSEcCtD
L-DOPA—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000204	0.000638	CcSEcCtD
L-DOPA—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000204	0.000637	CcSEcCtD
L-DOPA—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000204	0.000637	CcSEcCtD
L-DOPA—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000203	0.000634	CcSEcCtD
L-DOPA—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000202	0.000632	CcSEcCtD
L-DOPA—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000202	0.000632	CcSEcCtD
L-DOPA—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.0002	0.000625	CcSEcCtD
L-DOPA—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000199	0.000623	CcSEcCtD
L-DOPA—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000197	0.000616	CcSEcCtD
L-DOPA—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000197	0.000616	CcSEcCtD
L-DOPA—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000197	0.000615	CcSEcCtD
L-DOPA—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000196	0.000613	CcSEcCtD
L-DOPA—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000196	0.000613	CcSEcCtD
L-DOPA—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000195	0.000609	CcSEcCtD
L-DOPA—Rash—Indinavir—acquired immunodeficiency syndrome	0.000194	0.000607	CcSEcCtD
L-DOPA—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000194	0.000607	CcSEcCtD
L-DOPA—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000193	0.000605	CcSEcCtD
L-DOPA—Headache—Indinavir—acquired immunodeficiency syndrome	0.000193	0.000604	CcSEcCtD
L-DOPA—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000192	0.000602	CcSEcCtD
L-DOPA—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000191	0.000596	CcSEcCtD
L-DOPA—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00019	0.000593	CcSEcCtD
L-DOPA—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000188	0.000588	CcSEcCtD
L-DOPA—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000187	0.000585	CcSEcCtD
L-DOPA—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000185	0.000579	CcSEcCtD
L-DOPA—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.000578	CcSEcCtD
L-DOPA—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000184	0.000576	CcSEcCtD
L-DOPA—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000184	0.000574	CcSEcCtD
L-DOPA—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000183	0.000573	CcSEcCtD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000183	0.00137	CbGpPWpGaD
L-DOPA—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000183	0.000572	CcSEcCtD
L-DOPA—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000183	0.000571	CcSEcCtD
L-DOPA—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000182	0.00057	CcSEcCtD
L-DOPA—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000182	0.00057	CcSEcCtD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000182	0.00137	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000181	0.00136	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00018	0.00135	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00018	0.00135	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00018	0.00135	CbGpPWpGaD
L-DOPA—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.000556	CcSEcCtD
L-DOPA—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000177	0.000554	CcSEcCtD
L-DOPA—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000176	0.000551	CcSEcCtD
L-DOPA—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000176	0.000549	CcSEcCtD
L-DOPA—DRD5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000176	0.00132	CbGpPWpGaD
L-DOPA—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000175	0.000549	CcSEcCtD
L-DOPA—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000175	0.000548	CcSEcCtD
L-DOPA—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000174	0.000546	CcSEcCtD
L-DOPA—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000174	0.000545	CcSEcCtD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000174	0.00131	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000174	0.00131	CbGpPWpGaD
L-DOPA—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000173	0.000541	CcSEcCtD
L-DOPA—DRD2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000172	0.00129	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000171	0.00128	CbGpPWpGaD
L-DOPA—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00017	0.000533	CcSEcCtD
L-DOPA—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.000531	CcSEcCtD
L-DOPA—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00017	0.00053	CcSEcCtD
L-DOPA—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000167	0.000523	CcSEcCtD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000167	0.00125	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CCR5—acquired immunodeficiency syndrome	0.000167	0.00125	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000167	0.00125	CbGpPWpGaD
L-DOPA—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000165	0.000517	CcSEcCtD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000165	0.00124	CbGpPWpGaD
L-DOPA—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000164	0.000513	CcSEcCtD
L-DOPA—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000164	0.000512	CcSEcCtD
L-DOPA—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000162	0.000508	CcSEcCtD
L-DOPA—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000162	0.000507	CcSEcCtD
L-DOPA—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000162	0.000506	CcSEcCtD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000162	0.00121	CbGpPWpGaD
L-DOPA—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000161	0.000505	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—ALB—acquired immunodeficiency syndrome	0.00016	0.0012	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000159	0.00119	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000158	0.00119	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	0.000158	0.00119	CbGpPWpGaD
L-DOPA—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000158	0.000493	CcSEcCtD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000157	0.00118	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000157	0.00118	CbGpPWpGaD
L-DOPA—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000156	0.000489	CcSEcCtD
L-DOPA—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000156	0.000489	CcSEcCtD
L-DOPA—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000156	0.000488	CcSEcCtD
L-DOPA—DRD4—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000156	0.00117	CbGpPWpGaD
L-DOPA—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000155	0.000486	CcSEcCtD
L-DOPA—DRD2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000155	0.00117	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000155	0.00116	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000155	0.00116	CbGpPWpGaD
L-DOPA—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000478	CcSEcCtD
L-DOPA—DDC—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000151	0.00114	CbGpPWpGaD
L-DOPA—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.00015	0.00047	CcSEcCtD
L-DOPA—DRD4—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00015	0.00113	CbGpPWpGaD
L-DOPA—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000149	0.000466	CcSEcCtD
L-DOPA—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000149	0.000466	CcSEcCtD
L-DOPA—DRD2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000149	0.00112	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000149	0.00112	CbGpPWpGaD
L-DOPA—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000148	0.000463	CcSEcCtD
L-DOPA—DRD3—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000148	0.00111	CbGpPWpGaD
L-DOPA—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.00046	CcSEcCtD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000147	0.0011	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000145	0.00109	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000141	0.00106	CbGpPWpGaD
L-DOPA—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000439	CcSEcCtD
L-DOPA—DRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00014	0.00105	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—ALB—acquired immunodeficiency syndrome	0.00014	0.00105	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000139	0.00105	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000139	0.00105	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000139	0.00104	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	0.000139	0.00104	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000138	0.00104	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000137	0.00103	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000133	0.001	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000133	0.000996	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000133	0.000996	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000133	0.000995	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—IL2—acquired immunodeficiency syndrome	0.00013	0.000974	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00013	0.000973	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000127	0.000953	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000126	0.000948	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000126	0.000945	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000125	0.000942	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000125	0.000941	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000124	0.000929	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000123	0.000925	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	0.000123	0.000922	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.000122	0.000916	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	0.000121	0.000907	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000119	0.000896	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000119	0.000896	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000119	0.000896	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000119	0.000895	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000118	0.000889	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000118	0.000889	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000118	0.000884	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000118	0.000884	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000118	0.000884	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000117	0.00088	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000117	0.000876	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000115	0.000864	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000114	0.000854	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000113	0.00085	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000113	0.00085	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000112	0.000842	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000108	0.000814	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000108	0.000811	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000107	0.000807	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000106	0.000796	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000106	0.000796	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000106	0.000792	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CD4—acquired immunodeficiency syndrome	0.000105	0.000786	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000104	0.000781	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000104	0.000779	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000104	0.000779	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000102	0.000766	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000102	0.000762	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000102	0.000762	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000101	0.000757	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	9.96e-05	0.000748	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.81e-05	0.000736	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.59e-05	0.00072	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.47e-05	0.000711	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	9.38e-05	0.000704	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	9.22e-05	0.000692	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	9.22e-05	0.000692	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	9.09e-05	0.000682	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	9.09e-05	0.000682	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.02e-05	0.000677	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.02e-05	0.000677	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.01e-05	0.000676	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	8.96e-05	0.000673	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.81e-05	0.000661	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.59e-05	0.000645	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.18e-05	0.000614	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.11e-05	0.000609	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.08e-05	0.000606	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.03e-05	0.000603	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.01e-05	0.000601	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.97e-05	0.000598	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.97e-05	0.000598	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.73e-05	0.00058	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.66e-05	0.000575	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.66e-05	0.000575	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.61e-05	0.000571	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.5e-05	0.000563	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.5e-05	0.000563	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.24e-05	0.000543	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.21e-05	0.000541	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.18e-05	0.000539	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.11e-05	0.000534	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.08e-05	0.000532	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.02e-05	0.000527	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.96e-05	0.000523	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.92e-05	0.00052	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.91e-05	0.000519	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.89e-05	0.000517	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.89e-05	0.000517	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.86e-05	0.000515	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.81e-05	0.000511	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.81e-05	0.000511	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.8e-05	0.00051	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.8e-05	0.00051	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.75e-05	0.000507	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.75e-05	0.000507	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.66e-05	0.0005	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.66e-05	0.0005	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.52e-05	0.000489	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.43e-05	0.000483	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.41e-05	0.000481	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.32e-05	0.000474	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	6.24e-05	0.000468	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.23e-05	0.000468	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.18e-05	0.000464	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.15e-05	0.000462	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.13e-05	0.00046	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.13e-05	0.00046	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.05e-05	0.000454	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.05e-05	0.000454	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.8e-05	0.000435	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	5.78e-05	0.000434	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.7e-05	0.000428	CbGpPWpGaD
L-DOPA—PSIP1—Disease—IL6—acquired immunodeficiency syndrome	5.66e-05	0.000425	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.62e-05	0.000422	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.45e-05	0.000409	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.45e-05	0.000409	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.44e-05	0.000408	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.42e-05	0.000407	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	5.34e-05	0.000401	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.2e-05	0.000391	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.2e-05	0.000391	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	5.2e-05	0.00039	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.18e-05	0.000389	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.14e-05	0.000386	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.13e-05	0.000385	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	5.13e-05	0.000385	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.1e-05	0.000383	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.1e-05	0.000382	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.1e-05	0.000382	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.07e-05	0.00038	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.06e-05	0.00038	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.99e-05	0.000375	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.92e-05	0.000369	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.73e-05	0.000355	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.71e-05	0.000353	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.67e-05	0.00035	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.66e-05	0.00035	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.63e-05	0.000347	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.63e-05	0.000347	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.63e-05	0.000347	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.6e-05	0.000345	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.59e-05	0.000345	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.56e-05	0.000343	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	4.54e-05	0.000341	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.53e-05	0.00034	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.28e-05	0.000321	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.26e-05	0.00032	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.2e-05	0.000315	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.2e-05	0.000315	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.15e-05	0.000311	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.14e-05	0.000311	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.08e-05	0.000306	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ALB—acquired immunodeficiency syndrome	4.05e-05	0.000304	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.02e-05	0.000302	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.02e-05	0.000302	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.02e-05	0.000302	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.93e-05	0.000295	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.88e-05	0.000291	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.85e-05	0.000289	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.82e-05	0.000287	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.8e-05	0.000285	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.73e-05	0.00028	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.65e-05	0.000274	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.62e-05	0.000272	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.62e-05	0.000272	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.57e-05	0.000268	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.57e-05	0.000268	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.52e-05	0.000264	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.49e-05	0.000262	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.47e-05	0.00026	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.21e-05	0.000241	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.17e-05	0.000238	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.06e-05	0.00023	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.01e-05	0.000226	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.97e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.91e-05	0.000218	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.76e-05	0.000207	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.75e-05	0.000207	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.73e-05	0.000205	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.73e-05	0.000205	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.72e-05	0.000204	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.71e-05	0.000204	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.7e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.68e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.67e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.64e-05	0.000198	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.48e-05	0.000186	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.45e-05	0.000184	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.43e-05	0.000182	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.39e-05	0.00018	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.16e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.15e-05	0.000161	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.08e-05	0.000156	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.05e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.02e-05	0.000151	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.87e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.83e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.59e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.58e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.43e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.43e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.41e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.41e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.27e-05	9.52e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.08e-05	8.12e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.08e-05	8.08e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.36e-06	7.03e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	9.31e-06	6.99e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.43e-06	6.32e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.31e-06	6.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.36e-06	4.78e-05	CbGpPWpGaD
